Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2016

Open Access 01-12-2016 | Preliminary research

18F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma

Authors: J. C. Regelink, P. G. Raijmakers, N. Bravenboer, R. Milek, N. J. Hoetjes, A. M. de Kreuk, M. van Duin, M. J. Wondergem, P. Lips, P. Sonneveld, J. M. Zijlstra, S. Zweegman

Published in: EJNMMI Research | Issue 1/2016

Login to get access

Abstract

Background

Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared 18F-fluoride-PET with the MAR in myeloma patients.

Methods

Bone formation was measured before and after bortezomib treatment by determination of the MAR in iliac bone marrow biopsies and the measurement of 18F-uptake.

Results

The inter- and intra-individual variations in 18F-uptake (SUVA50%) were pronounced as 33.50 (range 4.42 to 37.92) and 27.18 (range 4.00 to 31.18), respectively. A significant correlation between the MAR and 18F-uptake was found (r = 0.80, p = 0.017). There was a heterogeneous response after treatment varying from −2.20 to 4.53.

Conclusions

Iliac 18F-uptake was associated with the local MAR in myeloma patients. Furthermore, 18F-fluoride-PET demonstrated the heterogeneity of in vivo bone formation, enabling monitoring during treatment.
Appendix
Available only for authorised users
Literature
1.
Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood. 2006;108:3992–6.CrossRefPubMed
2.
Von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia. 2007;9:2025–34.CrossRef
3.
Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol. 2006;135:688–92.CrossRefPubMed
4.
Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007;110:334–8.CrossRefPubMed
5.
Hawkins RA, Choi Y, Huang SC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633–42.PubMed
6.
Messa C, Goodman WG, Hoh CK, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol and Metab. 1993;77:949–55.
7.
Piert M, Zittel TT, Becker GA, et al. Assessment of porcine bone metabolism by dynamic [18F]fluoride ion PET: correlation with bone histomorphometry. J Nucl Med. 2001;42:1091–100.PubMed
8.
Raijmakers P, Temmerman OP, Saridin CP, et al. Quantification of 18F-fluoride kinetics: evaluation of simplified methods. J Nucl Med. 2014;7:1122–7.CrossRef
9.
Kobe C, Scheffler M, Holstein A, et al. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging. 2012;39:1117–27.CrossRefPubMed
10.
Puri T, Frost ML, Curran KM, et al. Differences in regional bone metabolism at the spine and hip: a quantitative study using (18)F-fluoride positron emission tomography. Osteoporos Int. 2013;2:633–9.CrossRef
11.
Lee SE, Min CK, Yahng SA, et al. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma. Eur J of Haem. 2010;86:83–6.
12.
Mick CG, James T, Hill JD, et al. Molecular imaging in oncology: (18)F-sodium fluoride PET imaging of osseous metastatic disease. Am J Roentgenol. 2014;203:263–71.CrossRef
13.
Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodelling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer. 2012;131:1466–71.CrossRefPubMed
Metadata
Title
18F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma
Authors
J. C. Regelink
P. G. Raijmakers
N. Bravenboer
R. Milek
N. J. Hoetjes
A. M. de Kreuk
M. van Duin
M. J. Wondergem
P. Lips
P. Sonneveld
J. M. Zijlstra
S. Zweegman
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2016
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-016-0197-4

Other articles of this Issue 1/2016

EJNMMI Research 1/2016 Go to the issue

Original research

Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy

Original research

Decreased renal AT1 receptor binding in rats after subtotal nephrectomy: PET study with [18F]FPyKYNE-losartan

Original research

Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour

Original research

The cingulate island sign within early Alzheimer’s disease-specific hypoperfusion volumes of interest is useful for differentiating Alzheimer’s disease from dementia with Lewy bodies

Original research

Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren’s syndrome treated with Infliximab: a pilot study

Short communication

Impact of fasting on 18F-fluorocholine gastrointestinal uptake and detection of lymph node metastases in patients with prostate cancer